1,2,3,4-四氢喹啉-2-羧酸甲酯 | 63430-79-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1,2,3,4-四氢喹啉-2-羧酸甲酯
• 英文名称: 1,2,3,4-tetrahydro-quinoline-2-carboxylic acid methyl ester
• 英文别名: methyl 1,2,3,4-tetrahydroquinoline-2-carboxylate
• CAS: 63430-79-5
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: ACEPYLDNGYGKDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2915900090

反应信息

• 作为反应物：
  描述：

  1,2,3,4-四氢喹啉-2-羧酸甲酯 在 盐酸 、 氯化亚砜 、 硫酸 、 palladium 10% on activated carbon 、 氢气 、 potassium nitrate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 21.0h， 生成 甲基6-氨基-1,2,3,4-四氢-2-喹啉羧酸酯
  参考文献：
  名称：

  Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists

  摘要：

  Prostate cancer (PC) is the most diagnosed type of malignancy in men and the major frequently cause of cancer-related death worldwide. The androgen receptor (AR) has become a promising drug target for the treatment of PC. Here, we reported the design, optimization and evaluation of pyridine tetrahydroisoquinoline thiohydantoin derivatives with improved activity and safety as potent AR antagonists. The most promising compound 42f exhibited potent inhibitory activity on AR and strongly blocked AR nuclear translocation. Moreover, 42f displayed promising in vitro antitumor activity toward AR-dependent prostate cancer cell lines (LNCaP) and also demonstrated therapeutic effects in LNCaP xenograft tumor model in mice (TGI: 79%) with no apparent toxicity observed in vivo. More importantly, 42f showed negligible penetration of the brain-blood barrier (BBB) compared with enzalutamide. These results provide a foundation for the development of a new class of androgen receptor antagonists for potential therapeutics against PC with lower seizurogenic risk for patients. (c) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112196
• 作为产物：
  描述：

  2-氨基苯乙醇 在 (S,S)-2,2'-异亚丙基双(4-苯基-2-恶唑啉) 、 potassium carbonate 、 一水合肼 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 四(3,5-二(三氟甲基)苯基)硼酸钠 、 三乙胺 、 甲烷磺酰基叠氮化物 、 sodium iodide 、 copper dichloride 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 53.08h， 生成 1,2,3,4-四氢喹啉-2-羧酸甲酯
  参考文献：
  名称：

  对映选择性铜催化分子内NH键插入：手性2-羧基四氢喹啉的合成。

  摘要：

  通过使用经手性螺双二恶唑啉配体改性的铜催化剂，实现了第一个高度对映选择性的分子内NH键插入，这为手性2-羧基四氢喹啉的合成提供了新的策略。该反应具有反应速度快，产率高，对映选择性高和反应条件温和的特点。

  DOI：

  10.1002/adsc.201600390

文献信息

• [EN] TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS<br/>[FR] DÉRIVÉS DE TÉTRAHYDROQUINOLINE UTILISÉS EN TANT QU'ACTIVATEURS D'AMPK
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012052372A1

  公开（公告）日：2012-04-26

  A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein R1 to R7 have the significance given in claim 1, can be used as a medicament.

  化合物的化学式（I），或其药学上可接受的盐或酯，其中R1至R7具有权利要求1中给定的含义，可用作药物。
• 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amide
  申请人：Novartis Corporation

  公开号：US05719141A1

  公开（公告）日：1998-02-17

  Compounds of the formula I ##STR1## in which R.sub.1 is arylamino, N-aryl-N-(lower alkoxy-lower alkyl)-amino, N-aryl-N-aryl-lower alkyl-amino or heterocyclyl bonded via a ring carbon atom, X is a carbonyl or methylene group, R.sub.2 and R.sub.3 independently of one another are hydrogen or lower alkyl or, together with the carbon atom with which they are bonded, are a cycloalkylidene radical, R.sub.4 is hydrogen, lower alkyl, lower alkanoyl or lower alkoxycarbonyl, R.sub.5 is hydroxyl, lower alkanoyloxy or lower alkoxycarbonyloxy, R.sub.6 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkyl-lower alkyl, aryl-lower alkyl or heteroaryl-lower alkyl having 5 to 7 ring atoms in the heteroaryl ring and R.sub.7 is hydrogen or lower alkyl, or R.sub.6 and R.sub.7, together with the carbon atom with which they are bonded, are a cydoalkylidene radical and R.sub.8 denotes an aliphatic, cycloaliphatic-aliphatic or heteroarylaliphatic radical, and their salts can be used as active ingredients for medicaments for treatment of high blood pressure.

  公式I的化合物##STR1##中，其中R.sub.1是芳基氨基，N-芳基-N-(较低烷氧基-较低烷基)-氨基，N-芳基-N-芳基-较低烷基-氨基或通过环碳原子连接的杂环基，X是羰基或亚甲基基团，R.sub.2和R.sub.3彼此独立地是氢或较低烷基，或者与它们连接的碳原子一起是环烷基亚甲基基团，R.sub.4是氢，较低烷基，较低烷酰基或较低烷氧羰基，R.sub.5是羟基，较低烷酰氧基或较低烷氧羰氧基，R.sub.6是氢，较低烷基，较低烯基，较低炔基，环烷基，环烷基-较低烷基，芳基-较低烷基或杂环芳基-较低烷基，在杂环芳基环中有5到7个环原子，R.sub.7是氢或较低烷基，或者R.sub.6和R.sub.7与它们连接的碳原子一起是环烷基亚甲基基团，R.sub.8表示脂肪，环脂肪-脂肪或杂环脂肪基团，它们的盐可用作治疗高血压药物的活性成分。
• Tricyclic quinoxalinediones
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：US05616586A1

  公开（公告）日：1997-04-01

  Tricyclic quinoxalinediones of the formula: ##STR1## wherein X is alkyl, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, etc.; R.sup.1 is H, etc.; R.sup.2 is H, alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkylalkyl, arylalkyl, substituted arylalkyl, aryl, or substituted aryl; W is H, CO.sub.2 R.sup.3, CO.sub.2 Y, CONR.sup.3 R.sup.4, CONR.sup.3 Y, CON(OR.sup.3)R.sup.4, COR.sup.3, CN, tetrazolyl, or substituted alkyl; R.sup.3 and R.sup.4 independently are H, alkyl, cycloalkyl, alkenyl, alkynyl, etc.; Y is mono-substituted alkyl or di-substituted alkyl; and n is an integer 0 or 1, or a pharmaceutically acceptable salt thereof, which are useful as a selective antagonist of glutamate receptor for the treatment or prevention of various diseases in animals including human being, for example, minimizing damage of central nervous system induced by ischaemic or hypoxylic conditions, treatment and/or prevention of neurodegenerative disorders, and further analgesics, antidepressants, anxiolitics, and anti-schizophrenics.

  Tricyclic quinoxalinediones的中文翻译：其中X是烷基、卤素、氰基、三氟甲基、硝基、羟基、氨基等；R.sup.1是H等；R.sup.2是H、烷基、环烷基、烯基、炔基、环烷基烷基、芳基烷基、取代芳基烷基、芳基或取代芳基；W是H、CO.sub.2 R.sup.3、CO.sub.2 Y、CONR.sup.3 R.sup.4、CONR.sup.3 Y、CON(OR.sup.3)R.sup.4、COR.sup.3、CN、四唑基或取代烷基；R.sup.3和R.sup.4独立地是H、烷基、环烷基、烯基、炔基等；Y是单取代烷基或双取代烷基；n是整数0或1，或其药学上可接受的盐，可用作选择性谷氨酸受体拮抗剂，用于治疗或预防动物包括人类的各种疾病，例如，减少由缺血或低氧条件引起的中枢神经系统损伤，治疗和/或预防神经退行性疾病，以及进一步的镇痛剂、抗抑郁药、抗焦虑药和抗精神分裂症药物。
• Novel N-acylated heterocycles
  申请人：Recordati S.A.

  公开号：US20030162777A1

  公开（公告）日：2003-08-28

  Described are compositions comprising a muscarinic receptor antagonist and an N-acylated heterocycle derivative having affinity for serotonergic receptors, and enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts thereof. The combination of a muscarinic receptor antagonist and an N-acylated heterocycle, or an enantiomer, diastereoisomer, N-oxide, polymorph, solvate or pharmaceutically acceptable salt thereof, is useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT 1A receptors.

  描述了包含一种肌氨酸受体拮抗剂和一种对5-HT 1A 受体具有亲和力的N-酰化杂环衍生物的组合物，以及它们的对映体、二对映体、N-氧化物、多型体、溶剂合物和药用可接受盐。肌氨酸受体拮抗剂和N-酰化杂环，或其对映体、二对映体、N-氧化物、多型体、溶剂合物或药用可接受盐的组合，在治疗患有下尿路神经肌肉功能障碍和与5-HT 1A 受体相关疾病的患者中是有用的。
• A General and Highly Selective Cobalt-Catalyzed Hydrogenation of N-Heteroarenes under Mild Reaction Conditions
  作者：Rosa Adam、Jose R. Cabrero-Antonino、Anke Spannenberg、Kathrin Junge、Ralf Jackstell、Matthias Beller

  DOI：10.1002/anie.201612290

  日期：2017.3.13

  Herein, a general and efficient method for the homogeneous cobalt‐catalyzed hydrogenation of N‐heterocycles, under mild reaction conditions, is reported. Key to success is the use of the tetradentate ligand tris(2‐(diphenylphosphino)phenyl)phosphine). This non‐noble metal catalyst system allows the selective hydrogenation of heteroarenes in the presence of a broad range of other sensitive reducible

  本文报道了在温和的反应条件下，N-杂环均相钴催化加氢的通用有效方法。成功的关键是使用四齿配体三（2-（二苯基膦基）苯基）膦。这种非贵金属催化剂体系可在多种其他敏感的可还原基团存在的情况下对杂芳烃进行选择性加氢。